Sobi Buys Back Shares for Incentive Program
Swedish biopharmaceutical company Sobi has decided to exercise its authorisation to repurchase shares. The move is aimed at securing the company's commitments under an employee incentive program.
Stockholm – Swedish biopharmaceutical company Swedish Orphan Biovitrum AB (Sobi), specializing in rare diseases, has resolved to proceed with a share repurchase program. The company's board of directors exercised an authorisation on July 15, 2026, which was previously granted by the Annual General Meeting.
The repurchase will encompass all of the company's issued Class C shares and is intended to ensure Sobi can fulfill its obligations under its long-term incentive program for employees. The shares will be repurchased at a price equivalent to 100 percent of their quotient value. The transactions are expected to take place between July 16 and November 6, 2026.
The company is acquiring the Class C shares, which were previously issued as part of the incentive program. The repurchase is conditional upon subscription and payment by Svenska Handelsbanken AB. Subsequently, the repurchased Class C shares are intended to be converted into common shares.
Upon completion, Sobi will hold a total of 10,290,974 own common shares. This action follows a resolution at the 2026 Annual General Meeting permitting such a repurchase to facilitate the incentive program. Sobi operates globally, focusing on therapies for rare diseases.